Sato, Honami
Kobayashi, Takahiro http://orcid.org/0000-0002-9914-7517
Kameoka, Yoshihiro
Teshima, Kazuaki
Watanabe, Atsushi
Yamada, Masahiro
Yamashita, Takaya
Noguchi, Shinsuke
Michisita, Yoshihiro
Fujishima, Naohito
Kuroki, Jun
Takahashi, Naoto
Funding for this research was provided by:
Otsuka Pharmaceutical
NOVARTIS Foundation (Japan) for the Promotion of Science
Pfizer Japan
Astellas Pharma
Ono Medical Research Foundation
Asahikasei
Akita University
Article History
Received: 27 September 2023
Accepted: 14 January 2024
First Online: 9 February 2024
Declarations
:
: Naoto Takahashi received honoraria from Otsuka, Novartis, and Pfizer. Naoto Takahashi received research funding from Otsuka, Novartis, Pfizer, Astellas, Asahikasei, and Ono.
: The multicenter prospective observational study was conducted in Akita prefecture, Japan. This study enrolled patients with AML who were judged ineligible for intensive chemotherapy by the attending physician and treated by VEN combination therapy. It was conducted in accordance with the 1964 Helsinki Declaration and approved by the Ethics Committee of Akita University (August 6, 2021/No. 2696). Written informed consent was obtained from all participants before enrollment.